子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | PEPTIDE DEFORMYLASE INHIBITORS | EP02721667 | 2002-04-04 | EP1383729A4 | 2006-04-19 | BHAT AJITA; CHRISTENSEN SIEGFRIED B IV; FRAZEE JAMES S; HEAD MARTHA S; LEBER JACK DALE; LI MEI |
| PDF inhibitors and novel methods for their use are provided. | ||||||
| 102 | Verfahren zur Herstellung von Cyclohexandion-carbonsäurederivaten mit herbizider und das Pflanzenwachstum regulierender Wirkung | EP85810441.7 | 1985-09-26 | EP0177450A1 | 1986-04-09 | Brunner, Hans-Georg, Dr.; Müller, Urs, Dr. |
Ein neues, optimiertes Verfahren zur Herstellung von Cyclohexandioncarbonsäurederivaten der Formel 1, welches in sehr guter Ausbeute im Eintopfverfahren durchgeführt werden kann, besteht darin, dass man zu einem Gemisch eines reaktionsfähigen Carbonsäurederivatives der Formel III
Die Cyclohexandion-carbonsäurederivate haben herbizide und den Pflanzenwuchs regulierende Wirkung. |
||||||
| 103 | Salts of treprostinil | US15614801 | 2017-06-06 | US09988334B2 | 2018-06-05 | Hitesh Batra; Vijay Sharma; Sanmin Yang; Yi Zhang |
| Provided are novel treprostinil salts as well as methods for making treprostinil salts. | ||||||
| 104 | Process for preparing soluble granules of salts of pyridine containing carboxylic acids | US12951100 | 2010-11-22 | US08669209B2 | 2014-03-11 | Franklin N. Keeney; Neil A. Foster; Martin C. Logan; Maria G. Perry |
| Soluble granule formulations of amine salts of pyridine containing carboxylic acids with improved handling properties are provided by an improved process in which the pyridine containing carboxylic acid is partially neutralized with an amine. | ||||||
| 105 | Process to prepare treprostinil, the active ingredient in Remodulin® | US13548446 | 2012-07-13 | US08497393B2 | 2013-07-30 | Hitesh Batra; Sudersan M. Tuladhar; Raju Penmasta; David A. Walsh |
| This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil. | ||||||
| 106 | Biphenyl compound selective agonists of gamma RAR receptors | US12213178 | 2008-06-16 | US08106235B2 | 2012-01-31 | Thibaud Biadatti; Etienne Thoreau |
| Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis. | ||||||
| 107 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | US12331659 | 2008-12-10 | US08106232B2 | 2012-01-31 | Sean G. Trapp; Michael R. Leadbetter; Daniel D. Long; John R. Jacobsen; Priscilla Van Dyke; Pierre-Jean Colson; Miroslav Rapta; Ying Yu |
| The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds. | ||||||
| 108 | Aminotetralin compounds as mu opioid receptor antagonists | US12331627 | 2008-12-10 | US08101791B2 | 2012-01-24 | Michael R. Leadbetter; Sean G. Trapp; Daniel D. Long; John R. Jacobsen; Sabine Axt |
| The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds. | ||||||
| 109 | Recovery of organic acids | US12548312 | 2009-08-26 | US08048655B2 | 2011-11-01 | Dan W. Verser; Timothy J. Eggeman |
| A method is disclosed for the recovery of an organic acid from a dilute salt solution in which the cation of the salt forms an insoluble carbonate salt. A tertiary amine and CO2 are introduced to the solution to form the insoluble carbonate salt and a complex between the acid and an amine. A water immiscible solvent, such as an alcohol, is added to extract the acid/amine complex from the dilute salt solution to a reaction phase. The reaction phase is continuously dried and a product between the acid and the solvent, such as an ester, is formed. | ||||||
| 110 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | US12630537 | 2009-12-03 | US20100204206A1 | 2010-08-12 | Thomas BOHME; Uwe GERLACH; Dirk GRETZKE; Heinz-Werner KLEEMANN; Stefania PFEIFFER-MAREK; Henning VOLLERT; Jean-Michel ALTENBURGER; Sergio MALLART |
| Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising themThe present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them. | ||||||
| 111 | Hydrogenation processes | US10534075 | 2003-11-18 | US07732634B2 | 2010-06-08 | Stuart Leon Soled; Andrzej Malek; James Clarke Vartuli; Jennifer Schaefer Feeley; Sabato Miseo; Shifang Luo; Richard Henry Schlosberg; Joseph Ernest Baumgartner; Christine E. Kliewer; Steven T. Ragomo |
| The present invention is directed to a process for hydrogenating one or more organic compounds especially unsaturated organic compounds by bringing the compound into contact with a hydrogen-containing gas in the presence of a catalyst, which comprises one or more catalytically active metals applied to a porous catalyst support. The one or more catalytically active metals having been derived via a decomposed organic complex of the metal on the support, in particular amine complexes of the metal. The decomposed complex may be treated with hydrogen to activate the catalyst before use as a hydrogenation catalyst. | ||||||
| 112 | Amino Acid Derivatives | US12093503 | 2006-11-06 | US20090227680A1 | 2009-09-10 | Simon John Mantell |
| The present invention relates to a method of treating pain using a compound of formula (I), wherein Ar, R1, R3 and R3a are as defined herein. The invention also relates to certain novel compounds of formula (I). | ||||||
| 113 | Process of obtaining type II dehydroquinase enzyme inhibitors and precursors thereof | US10565348 | 2004-07-16 | US07563896B2 | 2009-07-21 | Concepción González Bello; Luis Castedo Expósito |
| The present invention relates to a process of obtaining type II dehydroquinase enzyme inhibitors and the precursors thereof from (−)-quinic acid. The described compounds have a carboxycyclohexene structure. The process of preparing the compounds and their application as compositions with pharmacological properties and herbicides of interest are described. | ||||||
| 114 | Antidiabetic bicyclic compounds | US11801841 | 2007-05-11 | US07442808B2 | 2008-10-28 | Min Ge; Jiafang He; Fiona Wai Yu Lau; Gui-Bai Liang; Songnian Lin; Weiguo Liu; Shawn P. Walsh; Lihu Yang |
| Tricyclic compounds containing a cyclopropyl carboxylic acid or carboxylic acid derivative (e.g. amide) fused to a bicyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | ||||||
| 115 | Labeling reactant | US11607045 | 2006-12-01 | US07381420B2 | 2008-06-03 | Jari Hovinen; Jari Peuralahti; Veli-Matti Mukkala |
| This invention concerns novel labeling reactants suitable for labeling of a biospecific binding reactant using solid-phase synthesis. The novel reactants are derivatives of diethylenetriaminepentaacetic acid (DTPA), wherein a suitable group is linked to the DTPA molecule, thus allowing site specific introduction of the ligand of the derivatives to bioactive molecules on solid phase in an oligopeptide synthesizer. | ||||||
| 116 | PROCESS FOR PREPARING CYCLODODECATRIENE | US11688505 | 2007-03-20 | US20070265184A1 | 2007-11-15 | Jurgen Herwig; Wilhelm Brugging; Martin Roos; Norbert Wilczok |
| Preparation of cyclododecatriene in a continuous or discontinuous process by trimerization of butadiene in the presence of a catalyst system and a solvent, the crude cyclododecatriene obtained being able to be isolated by means of distillation. The cyclooctadiene formed as by-product can likewise be isolated from the crude product. | ||||||
| 117 | Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | US10789324 | 2004-02-27 | US07173151B2 | 2007-02-06 | Christian Stapper; Heiner Glombik; Eugen Falk; Dirk Gretzke; Jochen Goerlitzer; Stefanie Keil; Hans-Ludwig Schaefer; Wolfgang Wendler |
| The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives.What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved. | ||||||
| 118 | Surface coating agents | US10395982 | 2003-07-14 | US06924390B2 | 2005-08-02 | Dale G. Swan |
| Compounds useful as surface coating agents, including compounds of the formula: wherein X1 comprises a first photoreactive species; X2 comprises a second photoreactive species; Y comprises a nonpolymeric core molecule comprising an aromatic group; and Z comprises at least one charged group. The Y core can include an aromatic group such as a benzene radical, the charged groups Z can be independently selected from the organic acids that include sulfonic acid, carboxylic acid, and phosphoric acid, and the photoreactive species of X1 and X2 can independently be aryl ketones, such as those selected from the group acetophenone, benzophenone, anthraquinone, anthrone, and anthrone-like heterocycles, and their substituted derivatives. Examples of such coating agents include 4,5-bis(4-benzoylphenylmethyleneoxy)benzene-1,3-disulfonic acid di(potassium and/or sodium) salt, 2,5-bis(4-benzoylphenylmethyleneoxy)benzene-1,4-disulfonic acid di(potassium and/or sodium) salt (Compound II), and 2,5-bis(4-benzoylphenylmethyleneoxy)benzene-1-sulfonic acid monopotassium and/or monosodium salt. | ||||||
| 119 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | US667664 | 1996-06-21 | US5741896A | 1998-04-21 | Vidyasagar Vuligonda; Min Teng; Richard L. Beard; Alan T. Johnson; Yuan Lin; Roshantha A. Chandraratna |
| Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity. | ||||||
| 120 | Processes for the preparation of cyclopropanecarboxylic acid and derivatives thereof | US315462 | 1994-09-30 | US5504245A | 1996-04-02 | Shaowo Liang; Timothy W. Price |
| Disclosed is a process for the preparation of cyclopropanecarboxylic acid by the non-catalytic, oxidation of cyclopropanecarboxaldehyde using molecular oxygen as the oxidant. Also disclosed are processes for the preparation of amides, esters and acid chlorides from cyclopropanecarboxylic acid. | ||||||
QQ群二维码
意见反馈
意见反馈